Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares traded down 5.1% during trading on Wednesday . The company traded as low as $71.13 and last traded at $72.08, with a volume of 1,018,671 shares trading hands. The stock had previously closed at $75.95.

A number of research analysts have commented on the company. Jefferies Group set a $109.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Sunday. Wedbush restated an “outperform” rating and issued a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Monday. Leerink Swann restated an “outperform” rating and issued a $94.00 target price (up previously from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Canaccord Genuity set a $120.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley restated a “hold” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.89.

The company’s 50-day moving average is $67.59 and its 200-day moving average is $63.06. The stock’s market capitalization is $2.91 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/ultragenyx-pharmaceutical-inc-rare-stock-price-down-5-1.html

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same period last year, the company posted ($0.83) earnings per share. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.96) earnings per share for the current year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $67.61, for a total transaction of $1,352,200.00. Following the completion of the transaction, the chief executive officer now owns 493,244 shares in the company, valued at $33,348,226.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.

A number of institutional investors have recently bought and sold shares of RARE. Wellington Management Group LLP boosted its position in Ultragenyx Pharmaceutical by 79.9% in the first quarter. Wellington Management Group LLP now owns 4,132,430 shares of the biopharmaceutical company’s stock worth $261,625,000 after buying an additional 1,835,196 shares during the last quarter. Vanguard Group Inc. boosted its position in Ultragenyx Pharmaceutical by 4.9% in the second quarter. Vanguard Group Inc. now owns 2,589,718 shares of the biopharmaceutical company’s stock worth $126,664,000 after buying an additional 120,999 shares during the last quarter. BlackRock Fund Advisors boosted its position in Ultragenyx Pharmaceutical by 1.6% in the first quarter. BlackRock Fund Advisors now owns 1,442,851 shares of the biopharmaceutical company’s stock worth $91,347,000 after buying an additional 23,389 shares during the last quarter. State Street Corp boosted its position in Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock worth $81,315,000 after buying an additional 300,901 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in Ultragenyx Pharmaceutical by 32.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 638,500 shares of the biopharmaceutical company’s stock worth $31,229,000 after buying an additional 155,000 shares during the last quarter. Institutional investors and hedge funds own 93.06% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.